Shorts

Karie Runcie, MD, provided next steps for improving outcomes in genitourinary cancers, specifically related to kidney cancer.

0:38

Leveraging Neoadjuvant Strategies to Bolster Cure Rates in Kidney Cancer

13 hours ago

Karie Danielle Keera Runcie, MD

A recent study that found 10.6% of patients developed a new mental health disorder within 1 year of their cancer diagnosis.

1:16

What New Tools Can Improve Mental Health Screening in Cancer Care?

16 hours ago

Julian C. Hong, MD, MS

Karie Runcie, MD, highlighted research she conducted as part of the phase 2 Cyto-KIK trial, a single-arm study assessing cabozantinib and nivolumab in metastatic kidney cancer prior to cytoreductive nephrectomy.

0:49

Cabozantinib Combo Displays Feasibility in Metastatic Kidney Cancer Group

2 days ago

Karie Danielle Keera Runcie, MD

Oxybutynin offered comparable ‘speed-to-relief’ vs comparators among patients experiencing hot flashes while on androgen deprivation therapy for prostate cancer, according to Bradley J. Stish, MD.

0:44

Offering Rapid Relief of Treatment-Emergent Hot Flashes in Prostate Cancer

2 days ago

Bradley J. Stish, MD

$Following the FDA approval of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory multiple myeloma, María-Victoria Mateos, MD, PhD, spoke with CancerNetwork® about how findings from the phase 3 MajesTEC-3 trial (NCT05083169) support the regimen’s clinical utility.$

0:45

Teclistamab/Daratumumab: An Exciting Combination in R/R Multiple Myeloma

7 days ago

Maria-Victoria Mateos, MD, PhD

Despite accounting for less than 1% of prostate cancer diagnoses, neuroendocrine prostate cancer (NEPC) is associated with suboptimal outcomes in the space, according to Rahul Aggarwal, MD.

0:49

Highlighting an Unmet Need in Neuroendocrine Prostate Cancer

7 days ago

Rahul R. Aggarwal, MD

The phase 3 CHALLENGE trial established a significant survival advantage among patients with colorectal cancer who underwent a structured exercise program, according to Linda Carlson, PhD, RPsych.

1:05

Could Exercise Be Prescribed as a Standard of Care for Cancer Treatment?

8 days ago

Linda E. Carlson, PhD

In a discussion with CancerNetwork®, Guenther Koehne, MD, highlighted the rapid development of therapeutic options in the multiple myeloma field, which has seen an increase in novel immunotherapies and a decrease in the use of chemotherapy.

0:48

Is a Functional Cure Possible in Multiple Myeloma Therapy?

9 days ago

Guenther Koehne, MD

0:30

Care Coordination Experiences in Breast Cancer

9 days ago

Nicole Arrato, PhD

Joaquim Bellmunt, MD, PhD, discussed the emergence of EVP as a standard of care regardless of fitness among all cisplatin-eligible MIBC populations.

1:21

Affirming Enfortumab Vedotin/Pembrolizumab as a Standard Across MIBC Groups

10 days ago

Joaquim Bellmunt, MD, PhD

In a conversation with CancerNetwork®, Nicolaus Kröger, MD, detailed how JAK inhibition can work in tandem with transplantation to improve outcomes among patients with myelofibrosis.

0:35

JAK Inhibitors May Improve Transplantation Outcomes in Myelofibrosis

14 days ago

Nicolaus Kröger, MD

Joy Li, MD, discussed findings from a retrospective analysis of patients treated with enfortumab vedotin with or without pembrolizumab in the adjuvant setting for at least 2 cycles of treatment at the 2026 ASCO GU Symposium.

1:04

Should You Discontinue Therapy for Urothelial Carcinoma During Toxicity?

14 days ago

Joy Li, MD

0:34

Study Finds 80% of Young Cancer Survivors Face Sexual Dysfunction

15 days ago

Chiara Acquati, PhD, LMSW, FAOSW

Benjamin Garmezy, MD, discussed safe management practices for treatment-emergent adverse effects (TEAEs) with MRT-2359 plus enzalutamide in the treatment of androgen receptor ligand-binding domain-mutated metastatic castration-resistant prostate cancer.

0:49

Examining Optimal Management Strategies for MRT-2359 in LBD-Mutant CRPC

16 days ago

Benjamin Garmezy, MD

1:07

When Do New Mental Health Disorders Occur Most in Patients with Cancer?

16 days ago

Julian C. Hong, MD, MS

1:03

Chemobrain Vs Dementia: Understanding the Difference

16 days ago

Yesne Alici, MD

In a discussion with CancerNetwork®, Natalia Neparidze, MD, spoke about the importance of minimal residual disease (MRD) as a relevant end point for clinical trials assessing novel therapeutic strategies among patients with multiple myeloma.

0:40

MRD is ‘Exceedingly Helpful’ in Assessing Multiple Myeloma Disease Course

16 days ago

Natalia Neparidze, MD

After the FDA granted priority review to rusfertide as a potential therapeutic option for patients with polycythemia vera, CancerNetwork® spoke with Andrew Kuykendall, MD, about what a potential FDA approval would mean for these patients.

0:45

Rusfertide Approval Would Move Past ‘Archaic’ Polycythemia Vera Standard

17 days ago

Andrew T. Kuykendall, MD

Maha Hussain, MD, MBChB, discussed advantages associated with docetaxel-containing triplet regimens for this patients with metastatic HSPC following a Medical Crossfire session she was a presenter for.

1:22

Triplet Therapy Appears to Be Generally Well Tolerated in Metastatic HSPC

17 days ago

Maha Hussain, MD

Tanya Dorff, MD, discussed findings from her presentation comparing doublet and triplet regimens among patients with hormone-sensitive prostate cancer within a Medical Crossfire session held at the New York GU Cancers Congress.

1:34

Delineating Distinct Advantages With Doublet Therapy in HSPC

18 days ago

Tanya B. Dorff, MD

0:34

Exploring AI Use in Breast Radiation Oncology

21 days ago

Molly Ingersoll, PhD, discussed the background behind an analysis, which assessed biological differences underlying sex- and gender-based disparities in bladder cancer outcomes.

0:40

Highlighting Sex-Based Disparities in Bladder Cancer Outcomes

21 days ago

Molly Ingersoll, PhD

In this GU Gemstone, Tanya Barauskas Dorff, MD, spoke with CancerNetwork at NY GU.

0:39

GU Gemstones: Tanya B. Dorff, MD

22 days ago

Tanya B. Dorff, MD

Sympathetic nerves actively signal to cancer-associated fibroblasts within the pancreatic tumor microenvironment, inducing a state that promotes tumor aggression.

0:57

Denervation Shows Different Pancreatic Tumor Reductions Across Sexes

22 days ago

Sebnem Ece Eksi, PhD

0:43

Is Proton Therapy Clinically Effective in Breast Cancer?

22 days ago

Chirag Shah, MD

0:44

MajesTEC-3 Trial Shows ‘Remarkable’ Outcomes in R/R Multiple Myeloma

23 days ago

Rajshekhar Chakraborty, MD

During a visit to Columbia University Herbert Comprehensive Cancer Center, CancerNetwork® spoke with Nicole Lamanna, MD, about the implications of the phase 3 AMPLIFY trial (NCT03836261) showing improved efficacy with acalabrutinib (Calquence) plus venetoclax (Venclexta) vs standard of care among patients with chronic lymphocytic leukemia (CLL).

0:31

AMPLIFY Trial Affirms Shift Away From Chemoimmunotherapy in CLL

23 days ago

Nicole Lamanna, MD

Sahil Doshi, MD, discussed the potential for dose reduction strategies with ipilimumab and nivolumab for the treatment of patients with advanced clear cell renal cell carcinoma.

1:14

Considering Reduced Dose Immunotherapy for Frail Metastatic ccRCC Groups

24 days ago

Sahil D. Doshi, MD

In a visit to Columbia University Herbert Irving Cancer Research Center, CancerNetwork® spoke with Brian Henick, MD, about potential adverse effects that may arise with the use of prophylactic steroids for patients who undergo immunotherapy for lung cancer and other diseases.

0:53

Addressing Steroid-Related Toxicities During Immunotherapy for Lung Cancer

25 days ago

Brian Henick, MD

In a recent visit to Columbia University Irving Cancer Research Center, expert researchers and clinicians shared insights on critical therapeutic developments across their respective disciplines.

Shorts

Trending on CancerNetwork

Anbenitamab Injection Combo Meets pCR End Point in HER2+ Breast Cancer

CAR-T Moves to the Front Line: Rethinking the Multiple Myeloma Sequence

Urine-Based Biopsy Shows 97.8% Sensitivity in Prostate Cancer Detection

ELCC 2026: Key Updates Across Non–Small Cell Lung Cancer Populations

Rewriting the Tumor Microenvironment With IL-12–Armored CAR T Cells